Novo Nordisk’s diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular benefits as the injectable forms of the drug, researchers reported at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback